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α-Synuclein accumulation is a pathological hallmark of Parkinson's
disease (PD). Ubiquitinated α-synuclein is targeted to proteaso-
mal or lysosomal degradation. Here we identify SUMOylation as
a major mechanism that counteracts ubiquitination by different
E3 ubiquitin-ligases and regulates α-synuclein degradation. We
report that PIAS2 promotes SUMOylation of α-synuclein, leading
to a decrease in α-synuclein ubiquitination by SIAH and Nedd4
ubiquitin ligases, and causing its accumulation and aggregation
into inclusions. This was associated with an increase in α-synuclein
release from the cells. A SUMO E1 inhibitor, ginkgolic acid, de-
creases α-synuclein levels by relieving the inhibition exerted on α-
synuclein proteasomal degradation. α-Synuclein disease mutants
are more SUMOylated compared to the wild type protein, and this
is associated with increased aggregation and inclusion formation.
We detected a marked increase in PIAS2 expression along with
SUMOylated α-synuclein in PD brains, providing a causal mecha-
nism underlying the upregulation of α-synuclein SUMOylation in
the disease. We also found a signiﬁcant proportion of Lewy bodies
in nigral neurons containing SUMO1 and PIAS2. Our observations
suggest that SUMOylation of α-synuclein by PIAS2 promotes α-
synuclein aggregation by two mutually reinforcing mechanisms.
First, it has a direct pro-aggregatory effect on α-synuclein. Sec-
ond, SUMOylation facilitates α-synuclein aggregation by blocking
its ubiquitin-dependent degradation pathways and promoting its
accumulation. Therefore, inhibitors of α-synuclein SUMOylation
provide a strategy to reduce α-synuclein levels and possibly ag-
gregation in PD.
Parkinson's disease j a-synuclein j SUMOylation j ubiquitination j
aggregation
Parkinson's disease (PD) is caused by progressive degenera-
tion of dopaminergic neurons in the substantia nigra (1). Muta-
tions andmultiplications of the α-synuclein gene cause autosomal
dominant PD (2). α-Synuclein is a major component of Lewy
bodies in sporadic PD and its accumulation is also a feature
of Dementia with Lewy Bodies (DLB) and Multiple System
Atrophy (MSA) (3, 4). It has been suggested that aggregated α-
synuclein can spread to different brain regions (5). On the other
hand, primary accumulation and aggregation of intracellular α-
synuclein is widely regarded as a failure of degradation mecha-
nisms (6, 7). Therefore, preventing α-synuclein accumulation is a
major goal for novel therapies. Although α-synuclein is degraded
by proteasomal, lysosomal and autophagic pathways (8-10), the
mechanisms that modulate its degradation remain obscure.
Lewy bodies are heavily ubiquitinated and α-synuclein pu-
rified from Lewy bodies is monoubiquitinated (11-13). Several
ubiquitin-ligases are capable of ubiquitinating α-synuclein (8, 14-
17). The E3 ubiquitin-ligase SIAH interacts with and monoubiq-
uitinates α-synuclein (8, 17). SIAH is present in Lewy bodies (8)
and monoubiquitinates α-synuclein at the same lysine residues
that aremonoubiquitinated in Lewy bodies (11, 17).Monoubiqui-
tinated α-synuclein is degraded by the proteasome (18-20) while
polyubiquitination by Nedd4 leads to its lysosomal degradation
(15).
We previously found that the deubiquitinase USP9X dynam-
ically deubiquitinates α-synuclein (18). Deubiquitination of α-
synuclein by USP9X impairs SIAH-dependent α-synuclein pro-
teasomal degradation and promotes degradation by autophagy
(18). Another deubiquitinase, USP8, removes K63-linked ubiqui-
tin chains of α-synuclein and prevents its lysosomal degradation
(21). The regulation of α-synuclein ubiquitination processes and
their role in α-synuclein homeostasis are still unclear.
α-Synuclein is also conjugated to SUMO (small ubiquitin-
like modifier) at lysines but its role in aggregation remains
controversial (22-25). Some studies demonstrated increased α-
synuclein aggregation by SUMOylation upon proteasomal inhi-
bition (23, 24), but SUMOylation itself had limited or no effect
on aggregation (22, 25). A lack of knowledge about the en-
dogenous α-synuclein SUMO-ligase hampered further progress
in determining the physiological and pathological functions of
α-synuclein SUMOylation. Therefore, we sought to identify the
endogenous SUMO ligase for α-synuclein and to determine how
SUMOylation affects α-synuclein ubiquitination, degradation,
and aggregation. Our data highlights a new role of SUMOylation
in dynamically regulating α-synuclein levels and pathology.
Results
Interaction and SUMOylation of α-synuclein by PIAS2
We found that PIAS2 co-immunoprecipitated with α-
synuclein from transfected cells (Fig. 1A), rat brain tissues (Fig.
1B), and in in vitro pull-down assays (Fig. S1A). The close ho-
mologue PIAS1 also interacted with α-synuclein in transfected
Signiﬁcance
Our work uncovers SUMOylation as a major regulator of
α-synuclein fate and pathological aggregation. SUMOyla-
tion promotes α-synuclein accumulation by counteracting
α-synuclein ubiquitination and inhibiting its degradation.
SUMOylation also directly causes aggregation of α-synuclein
in vitro and in cells, and the effects are much more prominent
with the α-synuclein disease mutants. Most importantly, levels
of SUMOylated α-synuclein and components of the SUMOy-
lation machinery increase several fold in PD brains and are
present in Lewy bodies. Our data indicate a major role of
SUMOylation in the pathological aggregation of α-synuclein
and Lewy body formation. Therefore, SUMOylation blockers
provide a novel strategy to prevent intracellular α-synuclein
accumulation, aggregation and spreading in PD.











































































































































Fig. 1. PIAS2 interacts with and SUMOylates α-synuclein. A, HA-α-Synuclein
from transfected HEK293 cells was immunoprecipitated with anti-HA an-
tibody (middle panel), and co-immunoprecipitation with PIAS1 or PIAS2
was detected with anti-myc (upper panel). Input levels were determined
using anti-myc (lower panel). Graph depicts the percent of myc-PIAS1 and
myc-PIAS2 co-immunoprecipitated with HA-α-synuclein relative to the total
amount of each myc protein added per immunoprecipitation. B, PIAS2
was immunoprecipitated from rat brain using anti-PIAS2 antibody (lower
panel), and co-immunoprecipitation was determinedwith anti-α-synuclein
antibody (upper panel). C, In vitroSUMOylation of α-synuclein by PIAS2. His-
α-synuclein was incubated with SUMOylation components and PIAS2. Levels
of SUMOylated α-synuclein in relation to non-SUMOylated α-synuclein were
quantiﬁedwith anti-α-synuclein (graph).D, SUMOylated proteins from trans-
fected HEK293 cells were immunoprecipitated with anti-Flag antibody and
immunoprecipitates were further incubated with the puriﬁed deSUMOylase
Ulp1 (lanes 3, 4 and 6). SUMOylated α-synuclein was detected with anti-α-
synuclein (ﬁrst panel). Immunoprecipitated SUMOylated proteins were de-
tected with anti-Flag antibody (second panel). Graph represents the percent
of SUMO-α-synuclein in cells (lanes 2 and 5) relative to non-SUMOylated α-
synuclein. E, PIAS2 knockdown decreases α-synuclein SUMOylation. HEK293
cells were transfected in the presence of siRNA control or a PIAS2 siRNA.
Graphs represent the percent of SUMO-α-synuclein in cells relative to non-
SUMOylated α-synuclein and the percent of PIAS2 relative to β-actin. Values
represent the average ± S.E.M. of 3 experiments. *, ** Different from control
at p < 0.05 and 0.01, respectively (Student’s t-test).
cells (Fig. 1A), in vitro pull-down assays (Fig. S1A) and rat brain
tissues (Fig. S1B). However, a direct comparison with PIAS2 in
cells and in in vitro binding assays indicates that the interaction of
Fig. 2. SUMOylation by PIAS2 prevents α-synuclein monoubiquitination.
A, Inhibition of SIAH-2-mediated monoubiquitination by PIAS2. In vitro
SUMOylation/ubiquitination reactions were carried out by incubating His-α-
synuclein with puriﬁed SUMOylation components for 60 min, followed by
the addition of ubiquitination components for another 60 min. Levels of
His-α-synuclein monoubiquitination were determined with anti-α-synuclein.
Graph shows the percent of SIAH-2-dependentα-synuclein monoubiquitina-
tion, with and without GST-PIAS2 by comparing lanes 2 and 4. B, PIAS2
inhibits Nedd4-mediated α-synuclein ubiquitination. Conditions were the
same as in A. Graph depicts the percent ofNedd4-dependentα-synuclein
ubiquitination in the absence and in the presence of GST-PIAS2. C, PIAS2
decreases α-synuclein monoubiquitination in cells. Ubiquitinated proteins
from transfected HEK293 cells were immunoprecipitated with anti-Flag
antibody and monoubiquitinated α-synuclein was detected with anti-α-
synuclein (ﬁrst panel). Graph depicts the percent of monoubiquitinated α-
synuclein in cells relative to unmodiﬁed α-synuclein. D, HEK293 cells were
transfected as indicated, and in the presence of siRNA control or PIAS2 siRNA.
Immunoprecipitation was carried out and analyzed as in C. Graph represents
the percent of monoubiquitinated α-synuclein in cells relative to unmodiﬁed
α-synuclein. Values represent the average ± S.E.M. of 3 experiments. *, **,
*** Different from control at p < 0.05, 0.01 and 0.001, respectively (Student’s
t-test).
α-synuclein and PIAS1 is much weaker than PIAS2 (Figs. 1A and
S1A). Thus, in subsequent experiments we studied in more detail











































































































































Fig. 3. SUMOylation by PIAS2 regulates α-synuclein levels and degrada-
tion. A, PIAS2 increases the steady-state levels of α-synuclein in transfected
HEK293 cells. Graph depicts the percent of α-synuclein steady-state levels
relative to β-actin at increasing amounts of myc-PIAS2. B, Endogenous levels
of α-synuclein increase upon myc-PIAS2 transfection. C, PIAS2 knockdown
decreases endogenous α-synuclein levels. HEK293 cells were transfected with
siRNA control or siRNA to PIAS2. Endogenous levels of α-synuclein were
determined using anti-α-synuclein antibody. D, PIAS2 prolongs α-synuclein
half-life in transfected HEK293 cells treatedwith 50 μMcycloheximide. Graph
depicts α-synuclein levels relative to β-actin in the presence of PIAS2 (●) or
control LacZ (○). E, PIAS2 elevates α-synucleinin extracellular medium. Levels
of α-synuclein in intracellular and extracellular HEK293 cell compartments
were monitored with anti-HA (upper panels). Total protein loading was
determined by Ponceau S staining (lower panels). Graph depicts the percent
of α-synuclein in the medium relative to total protein loading monitored by
Ponceau S staining. Values represent the average ± S.E.M. of 3-4 experiments.
*, **, *** Different from control at p < 0.05, 0.01 and 0.001, respectively.
Repeated measures one-way ANOVA with Bonferroni post-hoc test (A) or
Student’s t-test (B-E).
PIAS2 increased α-synuclein SUMOylation in vitro (Fig. 1C).
Basal levels of SUMOylated α-synuclein were observed in the
absence of PIAS2, which is consistent with the ability of the E2
conjugating enzyme UbcH9 to promote limited SUMO transfer
to substrates in the absence of E3 SUMO-ligases (26). Never-
theless, very small amounts of PIAS2, from 50ng per reaction,
significantly increased SUMOylated α-synuclein levels by almost
3 fold (Fig. 1C, graph). The size of the SUMOylated α-synuclein
product by PIAS2 was consistent with modifications by two in-
dividual SUMO1 molecules at two different sites, since SUMO1
alone cannot form polySUMO chains (27, 28). In agreement,
methylated SUMO, which does not allow the formation of chains
(29), did not affect the SUMOylation profile of α-synuclein (Fig.
Fig. 4. α-Synuclein disease mutants are more susceptible to SUMOylation
and aggregation. A, In vitroSUMOylationwas carried out by incubatingHis-α-
synuclein WT and disease variants with SUMOylation components, with and
without GST-PIAS2. Levels of His-α-synuclein SUMOylation were determined
with anti-α-synuclein antibody (ﬁrst and second panels). Third panel shows
a short exposure to reveal α-synuclein levels. Graph depicts the percent of in
vitro SUMOylated α-synuclein normalized to non-SUMOylated α-synuclein.B,
SUMOylated proteins from transfected HEK293 cells were immunoprecipi-
tated with anti-Flag antibody (second panel) and SUMOylated α-synuclein
was detected with anti-α-synuclein (ﬁrst panel). IgG heavy chain is indicated.
Graph depicts the percent of SUMOylated α-synuclein in cells normalized
to non-SUMOylated α-synuclein.C, SH-SY5Y cells were transfected with HA-
α-synuclein (wild type, A30P, A53T and E46K disease mutations) and Flag-
SUMO1, in the presence of myc-FKBP12 or myc-PIAS2. Cells were treated
with proteinase K before ﬁxation and processed for immunocytochemistry
with anti-HA antibody. Scale bar, 25 μm. Arrows in panel B’ indicate cells
with aggregates. D, SH-SY5Y cells were transfected, processed and analyzed
as in C. Graph represents the percentage of cells with HA-α-synuclein aggre-
gates.Values represent the average ± S.E.M. of 3 independent experiments. *,
**, *** Different fromWT at p < 0.05, 0.01 and 0.001, respectively (repeated
measures one-way ANOVA with Bonferroni post-hoc test).
S2A). In addition, we observed the accumulation of high molec-
ular weight α-synuclein species (above 250 kDa) in the presence
of PIAS2 with either SUMO1 or methylated SUMO1 (Figs. 1C
and S2A), suggesting the formation of α-synuclein aggregates, a
phenomenon characterized in detail in Fig. 5.
PIAS2 significantly increased α-synuclein SUMOylation
in cultured cells (Figs. 1D). Treatment of SUMO1-
immunoprecipitates with the purified deSUMOylase Ulp1 (30)
removed all SUMO conjugates and abolished the SUMOylated
α-synuclein signal (Fig. 1D, lanes 3, 4 and 6), confirming
the specificity of SUMO1-α-synuclein conjugates. Longer
exposure of the blots also demonstrates low levels of α-synuclein
SUMOylation in the absence of PIAS2 (Fig. S2B).
In agreement with its weaker binding to α-synuclein (Fig.
1A), PIAS1 promoted much less α-synuclein SUMOylation in
cells when compared to PIAS2 (Fig. S2C). On the other hand,
addition of the catalytic region of the E3 SUMO-ligase RanBP2











































































































































Fig. 5. Elevated SUMOylated α-synuclein and SUMOylation components
in PD brains. A, Homogenates prepared from substantia nigra of PD and
control patients were probed with anti-PIAS2 antibody (upper panel). Graph
depicts PIAS2 levels normalized to β-actin. B, Homogenates from frontal
cortex tissue of PD with dementia and matched controls were analyzed and
quantiﬁed as in A. C, Substantia nigra tissues of PD and controls patients
were homogenized in formic acid and probed with anti-SUMO1 antibody
(upper panel). Graph depicts SUMO1 levels normalized to β-actin. D, Ho-
mogenates from substantia nigra tissue ofPD and controls were incubated
with proteinase K for 30 minutes and probed with anti-SUMO1 antibody
(upper panel). A loading control was included by immediately adding 2%
SDS to the samples (lower panel). Graph depicts SUMOylated protein levels
of PD after 30 min proteinase K normalized to SUMOylated protein levels
in untreated substantia nigra samples. E, Homogenates from frontal cortex
tissues of PD with dementia and matched controls were immunoprecipitated
with anti-SUMO1 antibody (middle panel). Levels of SUMOylated α-synuclein
were determined using anti-α-synuclein antibody (upper panel). Lower panel
shows the input levels of α-synuclein.Graph depicts SUMOylated α-synuclein
levels normalized to non-SUMOylated α-synuclein. F, Immunohistochemistry
of substantia nigra from PD patients using anti-SUMO1 antibody. Control
lacks the primary antibody. Arrow points to a SUMO1-positive Lewy bodies.
Arrowheads point to control unstained Lewy bodies. Sections were counter-
stained with hematoxylin. Scale bars, 10μm. *, ** Signiﬁcantly different from
control at p < 0.05 and 0.01, respectively (Student’s t-test).
but without the formation of high molecular weight α-synuclein
species (Fig. S2D).
α-Synuclein has two lysine consensus sites for SUMOylation,
K96, and K102 (22). Nevertheless, mass spectrometry analysis
revealed that 11 of 15 α-synuclein lysines are SUMOylated (25).
In support of widespread SUMOylation of α-synuclein lysines by
PIAS2, we found that mutation of the α-synuclein lysines K96
and 102R decreased SUMOylation in cells by only 30% (Fig. 1D,
graph). Most importantly, partial knockdown of PIAS2 by siRNA
significantly decreased the levels of SUMOylated α-synuclein
(Fig. 1E). siPIAS2 also decreased the steady-state levels of α-
synuclein (Fig. 1E, fourth panel, characterized in detail in Fig. 3).
However, siPIAS2 still decreased the levels of SUMO-α-synuclein
by 50% after correcting for the lower steady-state levels of α-
synuclein (Fig. 1E, graph).
Inhibitory role of SUMOylation on α-synuclein ubiquitina-
tion
SUMOylation and ubiquitination target lysine residues, but
the relationship between these modifications has not been inves-
tigated for α-synuclein.We observed that in vitro SUMOylation by
PIAS2 decreased by 80% the monoubiquitination of α-synuclein
promoted by SIAH-2 (Fig. 2A, graph). In addition, we noticed a
decrease in PIAS2 levels in the presence of SIAH-2 (Fig. 2A, com-
pare lanes 3 and 4). This was due to the formation of high molec-
ular weight GST-PIAS2 species that were retained in the stacking
gel following the prolonged SUMOylation/monoubiquitination
assays, so that less monomeric GST-PIAS2 remained in the pres-
ence of SIAH-2 (Fig. S3). As control, the addition of PIAS2
without the SUMOylation components (SUMO E1 and UbcH9)
had no effect on in vitro α-synucleinmonoubiquitination (Fig. S4),
indicating that SUMOylation is responsible for the decrease in α-
synuclein monoubiquitination.
SUMOylation by PIAS2 significantly decreased the in vitro
ubiquitination of α-synuclein promoted by Nedd4 (Fig. 2B, com-
pare lanes 3 and 4, graph). Therefore, PIAS2-mediated SUMOy-
lation negatively modulates different forms of α-synuclein ubiq-
uitination.
Ectopic expression of PIAS2 lead to a 70% decrease in α-
synuclein monoubiquitination levels in cells (Fig. 2C, graph).
Conversely, PIAS2 knockdown by siRNA increased the levels of
monoubiquitinated α-synuclein by SIAH-2 by more than 2 fold
(Fig. 2D), supporting the role of PIAS2-mediated SUMOylation
in counteracting α-synuclein monoubiquitination in cells.
Role of SUMOylation in α-synuclein degradation
We found that PIAS2 increased the steady-state levels of α-
synuclein by up to 3 fold (Fig. 3A) but it did not modify the
steady-state levels of the control protein LacZ (Fig. S5). Endoge-
nous α-synuclein levels were increased 2 fold by PIAS2 overex-
pression (Fig. 3B), whereas PIAS2 knockdown downregulated
endogenous α-synuclein (Fig. 3C). Moreover, PIAS2 prolonged
the half-life of α-synuclein in the presence of the protein syn-
thesis inhibitor cycloheximide (Fig. 3D), suggesting that PIAS2-
dependent SUMOylation leads to α-synuclein accumulation by
reducing its degradation.
Since α-synuclein export has been proposed to spread PD,
we monitored extracellular α-synuclein levels. We found that
overexpression of PIAS2 increased the levels of extracellular α-
synuclein as well (Fig. 3E).
To explore the physiologic relevance of α-synuclein SUMOy-
lation, we used ginkgolic acid, an E1 SUMO inhibitor (31).
Ginkgolic acid decreased the steady-state levels of α-synuclein in
cells by up to 90% (Fig. S6A), and this was preventable by the pro-
teasome inhibitor lactacystin, suggesting that SUMOylation in-
hibition accelerates α-synuclein degradation by the proteasome.
Ginkgolic acid also downregulated the endogenous levels of α-
synuclein in primary neuronal cultures (Fig. S6B), confirming












































































































































We next investigated the presence of α-synuclein SUMOy-
lation in normal human brain tissue. We immunoprecipitated
SUMOylated proteins from human frontal cortex and identified
a SUMOylated α-synuclein signal in the human brain (Fig. S6C).
Treatment of the immunoprecipitate with the de-SUMOylase
Ulp1 abolished the SUMOylated-α-synuclein signal (Fig. S6C,
lane 2), indicating that SUMOylation of α-synuclein occurs in
vivo.
SUMOylation of mutant α-synuclein species and aggregation
SUMOylation of the α-synuclein disease mutants A30P,
A53T, and E46K was several-fold higher than the wild type α-
synuclein in vitro (Fig. 4A, graph). Addition of PIAS2 further in-
creased SUMOylation of allα-synuclein types, though the percent
of SUMOylation increase promoted by PIAS2 was similar among
wild type and disease mutants (Fig. 4A). Moreover, SUMOyla-
tion of the disease mutants by PIAS2 led to the formation of high-
molecular weight α-synuclein species suggestive of aggregates,
which weremuchmore prominent in all diseasemutants thanwild
type α-synuclein (Fig. 4A, middle panel).
α-Synuclein disease mutants were 2-3 times more SUMOy-
lated in cells in the presence of PIAS2 when compared to the wild
type protein (Fig. 4B). In agreement, the steady-state levels of
α-synuclein disease mutants were more pronouncedly increased
by PIAS2 compared with the wild type protein (Fig. S7A). Fur-
thermore, α-synuclein becomes partially resistant to proteinase
K treatment in the presence of PIAS2 (Fig. S7B), suggesting that
SUMOylation increases the aggregation state of α-synuclein in
cells. Resistance to proteinase K treatment wasmore pronounced
with α-synuclein disease mutants (Fig. S7B), which is compatible
with their higher aggregation state following PIAS2-mediated
SUMOylation.
We then investigated the aggregation and inclusion formation
of α-synuclein by immunocytochemistry. In order to improve the
sensitivity of our assay, we treated cells with proteinase K prior to
fixation for immunocytochemistry (32). Levels of proteinase K-
resistant α-synuclein aggregates were higher in disease mutants
than wild type in the presence of PIAS2 (Figs. 4C and 4D).
No significant inclusion formation was observed when a control
protein (myc-FKBP12) was transfected instead of myc-PIAS2
(Figs. 4C and 4D).Moreover, SUMO1 was present in α-synuclein
inclusions (Fig. S8).
Levels of SUMO-α-synuclein and SUMOylation machinery
in PD patients
Since α-synuclein SUMOylation takes place in normal human
brain tissues (Fig. S6C), we investigated the levels of PIAS2 in
PD brains. We observed that the levels of PIAS2 are about 3 fold
higher in the substantia nigra of PD patients (Fig. 5A) and in
the cerebral cortex of PD subjects that progressed to dementia
(Fig. 5B). Upon solubilization of brain tissues with formic acid
(33), the total levels of SUMOylated proteins are 2 fold higher in
the substantia nigra of PD brains compared to that of controls
(Fig. 5C). In addition, we treated with proteinase K to deter-
mine the levels of aggregated proteins (32, 34). The substantia
nigra of PD subjects contained significantly more proteinase K-
resistant SUMOylated proteins than controls (Figs. 5D). Most
importantly, the levels of SUMOylated α-synuclein isolated by
immunoprecipitation are strikingly increased in the cerebral cor-
tex of PD patients with dementia (Fig. 5E). In addition, we found
strong immunoreactivity of SUMO1 in approximately 25% (10
out of 41 α-synuclein-positive) Lewy bodies of 3 different PD
cases (Fig. 5F) while PIAS2 was detected in approximately 50%
(18 out of 37 α-synuclein-positive) Lewy bodies in 3 different PD
cases (Fig. S9).
Discussion
Our observations indicate that increased SUMOylation may play
a role in promoting α-synuclein accumulation and aggregation
in PD. We demonstrated that α-synuclein is SUMOylated by
PIAS2 and this is associated with α-synuclein accumulation, ag-
gregation and increased α-synuclein levels in the extracellular
medium. SUMOylation by PIAS2 promotes the formation of α-
synuclein inclusions in cells even in the absence of proteasome
inhibitors. Furthermore, SUMOylation decreases the ubiquiti-
nation of α-synuclein by both SIAH and Nedd4, indicating a
general inhibitory role of SUMOylation on α-synuclein ubiqui-
tination. Most importantly, SUMOylated α-synuclein and PIAS2
are markedly elevated in the substantia nigra of PD brains, and
Lewy bodies are positive for both SUMO1 and PIAS2.
We found that SUMOylation increases α-synuclein aggrega-
tion by two self-reinforcing mechanisms. First, SUMOylation by
PIAS2 directly promotes the aggregation of α-synuclein. Second,
SUMOylation impairs α-synuclein ubiquitination, which prevents
α-synuclein degradation. This causes the accumulation of α-
synuclein and facilitates its aggregation. In addition to blocking
α-synuclein degradation, SUMOylation by PIAS2 increased the
release of α-synuclein to the extracellular medium. The increase
in extracellular α-synuclein may be due to the α-synuclein accu-
mulation secondary to SUMOylation or indirectly by SUMOyla-
tion of the endosomal sorting complex, which is known to increase
α-synuclein extracellular export (35).
α-Synuclein contains two lysine residues, K96 and K102,
which follow the consensus for SUMOylation (22). A study using
α-synuclein mutated at K96 and K102 suggested that SUMOy-
lation of these residues decreases the aggregation of α-synuclein
(25). A caveat of using K96/102 mutants is that at least 9 addi-
tional α-synuclein lysines are SUMOylated in cells (25). In agree-
ment, we found that mutations on K96 and K102 caused only a
30% decrease in the SUMOylation of α-synuclein by PIAS2. In
support of our findings, SUMOylation of numerous proteins by
SUMO ligases occur in lysines that lack consensus sequence for
SUMO conjugation (36). Thus, the effects of K96/102 mutants on
aggregation observed in a previous study (25) may be related to
a change in the specific amino acids rather than SUMOylation
changes.
SUMOylation may have opposite effects on ubiquitination
of target proteins. It can either prime SUMO-targeted ubiquitin
ligases and increase ubiquitination or compete for the target
lysines preventing the ubiquitin linkage (37). The latter appears
to be the case for α-synuclein and PIAS2. In agreement, the
E1 SUMO inhibitor ginkgolic acid accelerated the proteasomal
degradation of α-synuclein by relieving the inhibition exerted on
its ubiquitination. This effect wasmore pronounced in transfected
cells than in neurons, suggesting that endogenous neuronal α-
synucleinmay have slower half-life or additional regulatorymech-
anisms that affect its proteasomal degradation, like glycation (38).
Previous studies reported that proteasomal inhibition pro-
motes α-synuclein inclusions that are SUMOylated but did not
ascribe a direct effect of SUMOylation on aggregation (23, 24).
Proteasomal inhibition also favors the formation of monoubiqui-
tinated α-synuclein aggregates (17, 18).We now show that PIAS2-
mediated SUMOylation per se increases the aggregation of α-
synuclein under intact proteasomal activity. It is possible that
akin to monoubiquitination (17), SUMOylation increases the hy-
drophobicity ofα-synuclein and directly facilitates its aggregation.
α-Synuclein may be SUMOylated by additional SUMO-
ligases, albeit with different efficiencies. We found that PIAS1
also interacts with α-synuclein in the brain, but direct comparison
by employing the same antibody for co-immunoprecipitations or
recombinant α-synuclein in pull down assays indicates weaker
interaction of human PIAS1 with α-synuclein when compared
to human PIAS2. In agreement with a previous study (25), we
found that the catalytic portion of RanBP2 SUMOylates α-
synuclein in vitro. However, we did not detect formation of high-











































































































































RanBP2 SUMOylation. In this context, it is possible that the
strong binding of PIAS2 to α-synuclein also contributes to the
efficient aggregation of SUMOylated α-synuclein, an effect not
shared by the catalytic part of RanBP2.
We found that the α-synuclein disease mutants are more
prone to SUMOylation and SUMOylation-mediated aggregation
than the wild type protein. Further studies are necessary to better
understand the mechanisms underlying the increased SUMOyla-
tion among α-synuclein disease mutants.
Abnormal SUMOylation has been implicated in the pathol-
ogy of neurodegenerative diseases, including Huntington’s,
Alzheimer’s and Amyotrophic Lateral Sclerosis (39-43). SUMO1
was also suggested to be present in some Lewy body prepara-
tions of PD and DLB brains (24). Unilateral rotenone-lesioned
mouse models of PD have increased levels of SUMO1 (44).
Our observation of a striking increase in SUMOylated proteins
and SUMOylated α-synuclein in PD tissues provides compelling
evidence supporting a general upregulation of SUMOylation in
PD and of the SUMOylated α-synuclein in particular. Our results
demonstrating an increase in PIAS2 expression in PD tissues and
the presence of SUMO1 and PIAS2 in Lewy bodies provides a
causal mechanism underlying the accumulation of SUMOylated
α-synuclein. Therefore, SUMOylation blockers may provide a
novel strategy to prevent intracellular α-synuclein aggregation
and the spread of α-synuclein.
Materials and Methods
In vitro SUMOylation assays
Recombinant His-α-synuclein was incubated in medium containing 40
mM Tris-HCl (pH 7.6), 5 mMMgCl2, 2 mM DTT, 1 mM ATP-γ-S, 5 μg SUMO1, 1
μM SUMO1 aldehyde, 100 ng SUMO E1 (SAE1/UBA2; activating enzyme) and
200 ng UbcH9 (SUMO E2; conjugating enzyme), in the presence or absence
of 200 ng PIAS2 or RanBP2△FG (E3 SUMO-ligases), unless speciﬁed otherwise.
Reactions were incubated at 370C for 1 hour and resolved on PAGE-SDS
gels. SUMOylated α-synuclein was determined by Western blot using anti-
α-synuclein antibody.
Further experimental details are provided in Supporting Information
text.
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